

TABLE OF CONTENTS

ILLUSTRATIONS IN THIS BOOK.....	iv
PSAP-VII EDITORIAL BOARD.....	v
WELCOME.....	vi
FACULTY POTENTIAL COI DISCLOSURE.....	vii
ROLE OF ACCP.....	vii
ROLE OF BPS.....	vii
CPE AND PROGRAM INSTRUCTIONS.....	viii
POSTTEST INSTRUCTIONS.....	viii

Infectious Diseases I.....	1
Infectious Diseases I Panel.....	3
Infectious Diseases I Subscriber Evaluation.....	5

HIV INFECTION AND AIDS

**P. Brandon Bookstaver, Pharm.D.,
BCPS (AQ Infectious Diseases), AAHIVE**

Introduction.....	7
Transmission and Testing.....	8
Pathophysiology and Disease Course.....	8
Treatment.....	9
Initiating Treatment.....	14
Acute HIV Syndrome.....	15
Roles of the Newest Antiretrovirals.....	15
Integrase Strand-Transfer Inhibitors.....	15
CCR5 Inhibitors.....	15
Nonnucleoside Reverse Transcriptase Inhibitors.....	16
Immune Reconstitution Inflammatory Syndrome.....	16
Mechanism and Presentation.....	16
Treatment.....	17
Risk Factors.....	17
Hepatitis Coinfection.....	17
HIV-HBV Coinfection.....	17
HIV-HCV Coinfection.....	18
Preexposure Prophylaxis.....	18
Postexposure Prophylaxis.....	18
Occupational.....	18
Nonoccupational.....	19
Opportunistic Infections.....	19
Epidemiology.....	19
Prophylaxis.....	19
Clinical Presentation and Treatment.....	21
Role of the Pharmacist.....	21
Conclusion.....	23
Annotated Bibliography.....	24
Self-Assessment Questions.....	29

PRIMARY CARE IN HIV

Jason J. Schafer, Pharm.D., BCPS, AAHIVE

Introduction.....	33
Cardiovascular Disease.....	34

HIV Infection and CVD Risk.....	34
ART and CVD Risk.....	35
Screening, Prevention, and Management.....	35
Alterations in Glucose Metabolism and DM.....	37
ART and Altered Glucose Metabolism.....	37
Screening.....	37
Management.....	38
Kidney Disease.....	38
Acute Kidney Injury.....	38
Chronic Kidney Disease.....	39
Screening and Prevention.....	39
Bone Disease.....	40
Osteopenia and Osteoporosis: The Role of ART.....	40
Screening.....	40
Non-AIDS-Defining Cancers.....	41
Risk Factors and Prevention.....	41
Screening and Management.....	42
Role of the Pharmacist.....	42
Annotated Bibliography.....	43
Self-Assessment Questions.....	49

TUBERCULOSIS

**Rocsanna Namdar, Pharm.D., BCPS; and
Charles A. Peloquin, Pharm.D., FCCP**

Introduction.....	53
Epidemiology and Risk Factors.....	53
Etiology.....	53
Pathophysiology.....	54
Latent Disease.....	54
Primary Infection.....	54
Reactivation Disease.....	54
Extrapulmonary.....	54
Clinical Presentation.....	54
Special Populations.....	54
Diagnosis and Prognosis.....	55
Diagnostic Testing.....	55
Culture and Susceptibility Testing.....	57
Quality Patient Care.....	57
TB Drugs.....	58
Treatment of Active Disease.....	61
Treatment in Special Populations.....	63
Role of the Pharmacist.....	65
Drug Monitoring.....	66
Therapeutic Drug Monitoring.....	66
Conclusion.....	66
Annotated Bibliography.....	66
Self-Assessment Questions.....	71

Infectious Diseases II.....	75
Infectious Diseases II Panel.....	77
Infectious Diseases II Subscriber Evaluation.....	79

ANTIMICROBIAL STEWARDSHIP

Marc H. Scheetz, Pharm.D., BCPS

(AQ Infectious Diseases); and

Michael Postelnick, BSPHarm, BCPS

(AQ Infectious Diseases)

Introduction	81
History	81
Goals	82
Multidisciplinary Approach	82
Antimicrobial Use in Hospital Systems	82
Antimicrobial Resistance	82
Escalating Costs	82
Methods of Tracking Stewardship Outcomes	83
Antimicrobial Use Measurements	83
Fiscal Measurements	84
Clinical Outcomes	84
Antimicrobial Stewardship Strategies	85
Preauthorization/Formulary Restriction	85
Prospective Audit and Feedback Strategies	86
Comparisons of Strategies	87
Recommendations from Professional Organizations	87
Role of the Pharmacist	87
Annotated Bibliography	87
Self-Assessment Questions	93

OPHTHALMIC AND OTIC INFECTIONS

By Ryan P. Moenster, Pharm.D., BCPS

(AQ Infectious Diseases)

Ophthalmic Infections	97
Pathogenesis, Clinical Manifestations, and Microbiology	97
Pharmacotherapy	101
Role of the Pharmacist	103
Otic Infections	105
Pathogenesis, Microbiology, and Diagnosis	105
Pharmacotherapy	106
Role of the Pharmacist	107
Annotated Bibliography	107
Self-Assessment Questions	111

CENTRAL NERVOUS SYSTEM INFECTIONS

Lisa M. Avery, Pharm.D., BCPS

Introduction	115
Epidemiology—Impact of Vaccines	116
Outcomes Associated with Delayed Therapy	116
Diagnosis	117
Rapid Diagnostic Testing	117
Blood Diagnostic Tests	117
Bacterial Meningitis Score	119
<i>S. pneumoniae</i>	119
Empiric Therapy	120
Patient Allergies/Drug-Resistant Strains	121
<i>N. meningitidis</i>	122

Prevention/Vaccination Guidelines	123
Inhibition of Inflammation Targets	124
Adjunctive Therapy—Corticosteroids	124
Nosocomial-Acquired Pathogens	124
Alternative Antibiotics for Multidrug-Resistant Organisms	125
Gram-positive Organisms	125
Gram-negative Organisms	125
Cryptococcal Meningoencephalitis	126
Updated Treatment Recommendations	126
Role of New Antifungals	126
Encephalitis	127
Herpes Simplex Virus-1 and -2	127
West Nile Virus	127
Role of the Pharmacist	128
Conclusion	128
Annotated Bibliography	128
Self-Assessment Questions	133

METHICILLIN-RESISTANT

S. AUREUS INFECTIONS

Vanthida Huang, Pharm.D.; and

Phillip Owen, Pharm.D., BCPS

Introduction	139
Epidemiology, Risk Factors, and Transmission	140
Molecular Characteristics of CA-MRSA and HA-MRSA	140
Management of MRSA Infections	141
Role of Incision and Drainage	141
Pharmacotherapy—First-line Agents	141
Combination Therapy: Rifampin and Fluoroquinolones	144
Alternative Therapies	145
Emerging Therapies	145
Prevention of MRSA Infection	146
Role of the Pharmacist	147
Quality Assurance	147
Conclusion	147
Annotated Bibliography	147
Self-Assessment Questions	153

Infectious Diseases III	157
Infectious Diseases III Panel	159
Infectious Diseases III Subscriber Evaluation	161

BONE AND JOINT INFECTIONS

Jamie S. Winner, Pharm.D., BCPS

(AQ Infectious Diseases)

Introduction	163
Bone Infections	163
Pathophysiology	163
Etiology	164
Diagnostic Criteria	165
Treatment	166

Joint Infections	168
Septic Arthritis	168
Prosthetic Joint Infections	169
Role of the Pharmacist	170
Outpatient Parenteral Antibiotic Therapy	170
Monitoring Plans	171
Conclusion	171
Annotated Bibliography	171
Self-Assessment Questions	175

INTRA-ABDOMINAL INFECTIONS

David T. Bearden, Pharm.D.

Introduction	179
Pathophysiology	179
Microbiology	180
Diagnostic Considerations	180
Clinical Presentation	180
Severity of Illness	180
Abbreviations in This Chapter	180
Treatment	181
Fluid Resuscitation	181
Source Control	181
Empiric Antibiotic Therapy	181
Monitoring	183
Role of the Pharmacist	184
Pharmacoeconomics	184
Appropriate Antimicrobial Use	184
Antimicrobial Stewardship	184
Conclusion	185
Annotated Bibliography	185
Self-Assessment Questions	189

C. DIFFICILE INFECTION

Kevin W. Garey, Pharm.D., M.S.

Introduction	193
History	193
Epidemiology and Economics	193
Microbiology and Pathophysiology	193
Clinical Presentation	195
Diagnosis of CDI	195
Treatment Goals	195
Pharmacotherapy	195
Alternative Therapies for CDI	198
Other Therapies for CDI	199
Role of the Pharmacist	199
Conclusion	199
Annotated Bibliography	199
Self-Assessment Questions	203

INFLUENZA

By Michael E. Klepser, Pharm.D., FCCP; and
Jennifer K. Hagerman, Pharm.D., AE-C

Introduction	207
Contemporary Epidemiology of Influenza Virus	208
Seasonal Influenza	208
Novel H1N1 Influenza A of Swine Origin	209
Influenza A H5N1	210
Diagnosis	210
Viral Culture	211
RT-PCR	211
Rapid Diagnostic Tests	212
Symptoms	212
Treatment of Confirmed or Suspected Influenza	213
Antiviral Therapy	213
Supportive Care	215
Antiviral Chemoprophylaxis	215
Treatment Indications	215
Antiviral Therapy	215
Outbreak Control	216
Vaccination	216
Role of the Pharmacist	220
Conclusion	220
Annotated Bibliography	220
Self-Assessment Questions	225

Reference Values for Common Laboratory Tests	230
--	-----